Protalix BioTherapeutics (PLX) Finished Goods (2012 - 2026)

Protalix BioTherapeutics' Finished Goods history runs 10 years deep, the most recent figure standing at $15.4 million for Q1 2026.

• On a quarterly basis, Finished Goods rose 119.15% year-over-year to $15.4 million in Q1 2026; TTM through Mar 2026 was $15.4 million, a 119.15% increase from a year earlier, with the FY2025 full-year figure at $10.4 million, up 90.38% from the prior year.
• Finished Goods rose to $15.4 million in Q1 2026 per PLX's latest filing, from $10.4 million in the prior quarter.
• Across five years, Finished Goods topped out at $15.4 million in Q1 2026 and bottomed at $706000.0 in Q3 2024.
• The 5-year median for Finished Goods is $9.2 million (2024), against an average of $9.0 million.
• Across the five-year window, Finished Goods plunged 91.46% in 2024 and surged 1446.32% in 2025, its largest moves.
• Year by year, Finished Goods stood at $10.6 million in 2022, then sank by 45.24% to $5.8 million in 2023, then slipped by 6.28% to $5.4 million in 2024, then soared by 90.38% to $10.4 million in 2025, then soared by 48.29% to $15.4 million in 2026.
• Per Business Quant, the three latest PLX Finished Goods figures stand at $15.4 million (Q1 2026), $10.4 million (Q4 2025), and $10.9 million (Q3 2025).